Profound Medical Corp.
PROF
$4.71
$0.183.97%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.83M | 2.44M | 1.38M | 1.20M | 428.00K |
| Total Other Revenue | 8.56M | 8.20M | 7.56M | 6.64M | 6.78M |
| Total Revenue | 11.39M | 10.21M | 8.51M | 7.41M | 6.78M |
| Cost of Revenue | 3.77M | 3.58M | 3.41M | 3.06M | 2.81M |
| Gross Profit | 7.62M | 6.63M | 5.10M | 4.35M | 3.97M |
| SG&A Expenses | 26.53M | 23.11M | 22.31M | 19.87M | 19.13M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.14M | 43.67M | 42.03M | 38.50M | 36.47M |
| Operating Income | -36.75M | -33.46M | -33.52M | -31.09M | -29.69M |
| Income Before Tax | -32.34M | -28.20M | -31.52M | -27.88M | -28.30M |
| Income Tax Expenses | 0.00 | -1.00K | 8.00K | -151.00K | -136.00K |
| Earnings from Continuing Operations | -32.34 | -28.20 | -31.53 | -27.73 | -28.17 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.34M | -28.20M | -31.53M | -27.73M | -28.17M |
| EBIT | -36.75M | -33.46M | -33.52M | -31.09M | -29.69M |
| EBITDA | -35.85M | -32.48M | -32.66M | -30.17M | -28.74M |
| EPS Basic | -1.23 | -1.14 | -1.34 | -1.22 | -1.29 |
| Normalized Basic EPS | -0.77 | -0.71 | -0.84 | -0.77 | -0.81 |
| EPS Diluted | -1.23 | -1.14 | -1.34 | -1.22 | -1.29 |
| Normalized Diluted EPS | -0.77 | -0.71 | -0.84 | -0.77 | -0.81 |
| Average Basic Shares Outstanding | 104.79M | 99.04M | 94.64M | 91.38M | 88.10M |
| Average Diluted Shares Outstanding | 104.79M | 99.04M | 94.64M | 91.38M | 88.10M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |